Devonian Health Group (GSD) Stock Price, News & Analysis

Company Overview

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada.

Key Stats

• Today's Range: C$7.50 to C$8.00
• 50-Day Range: C$6.70 to C$12.00
• 52-Week Range: C$5.10 to C$15.00
• Volume: 10,162 shs
• Average Volume: 2,118 shs
• Market Capitalization: C$22.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Technology
• Industry: Software
• Sub-Industry: Application Software
• Current Symbol: CVE:GSD
• CIK: N/A
• Web: www.groupedevonian.com
• Phone: 450-937-6696
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($2.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$3.17 million
• Net Margins: -32.50%
• Pretax Margin: N/A
• Return on Equity: -23.31%
• Return on Assets: -8.12%

Debt

• Debt-to-Equity Ratio: 16.36
• Current Ratio: 1.07
• Quick Ratio: 7.82

Sales & Book Value

• Annual Sales: C$3.00 million
• Price / Sales: 7.43
• Cash Flow: C$1.31 per share
• Price / Cash Flow: 6.10
• Book Value: C$0.09 per share
• Price / Book: 88.89

Miscellaneous

• Outstanding Shares: 2,781,000
• Free Float: N/A
• Market Cap: C$22.25 million
• Optionable: Not Optionable
• Beta: -0.35